

FREE is a next-generation tissue treatment

FREE addresses both causes of calcification: phospholipids and aldehydes

PHOSPHOLIPIDS REMOVAL

Phospholipids are intrinsically present in biological tissue. They are potential binding sites for calcium.¹

During the manufacturing process phospholipids are dissolved and eliminated

GLUTARALDEHYDE FIXATION AND STERILIZATION

After the phospholipids reduction, the tissue undergoes a fixation process to stabilize its mechanical properties, get sterilized and reduce immune response.¹

ENHANCED ALDEHYDE NEUTRALIZATION

Free aldehydes are a consequence of the fixation process. They favor toxicity and calcification.¹

Aldehydes are "capped" and neutralized during manufacturing



ALDEHYDE FREE STORAGE SOLUTION

Before packaging, the valve undergoes an industrialized rinsing process.

The valve is stored in an aldehyde-free solution, resulting in negligible toxicity for the patient and a faster procedure for the surgeon as no rinsing is required.²

calcification*







FREE is designed to improve durability²

* vs control group²

1. Thiene et al., The Journal of Heart Valve Disease 2011;20:37-44

2. Meuris et al., J Thorac Cardiovasc Surg. 2018 Jul;156(1):197-206

Technical claims are supported by Corcym data on file

The evolution of tissue treatments at CORCYM



FREE is one of the most advanced tissues you can choose for your patients

Treatment	Valve	Phospholipid removal	Aldehydes neutralization	No rinse required
FREE	PERCEVAL PLUS	\checkmark	\checkmark	\checkmark
RESILIA	INSPIRIS RESILIA	\checkmark	\checkmark	\checkmark
XENOLOGIX	PERIMOUNT PLATFORM	\checkmark	X	Х
THERMAFIX	MAGNA AND INTUITY PLATFORMS	\checkmark	\checkmark	Х
LINX	EPIC/ TRIFECTA	\checkmark	\checkmark	Х
AOA	MOSAIC/ FREESTYLE	\checkmark	\checkmark	Х
AOA	AVALUS	\checkmark	\checkmark	×

RESILIA, XENOLOGIX, THERMAFIX, INSPIRIS RESILIA, PERIMOUNT, MAGNA and INTUITY are commercialized by EDWARDS LIFESCIENCES; LINX EPIC, TRIFECTA are commercialized by ABBOTT; AOA, MOSAIC, FREESTYLE and AVALUS are commercialized by MEDTRONIC.

INTENDED USE/INDICATIONS

EUROPE: Perceval/Perceval Plus prosthesis is intended to replace a damaged native aortic heart valve or a malfunctioning aortic prosthesis via open heart surgery. The prosthesis is indicated for use in adult patients suffering from aortic valve stenosis or steno-insufficiency or with a previously implanted aortic valve prosthesis that is no longer functioning adequately and requires replacement. **US:** The Perceval/Perceval Plus bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves.

CANADA: The Perceval/Perceval Plus bioprosthesis is intended for use in patients aged \geq 65 years in which the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis.

AUSTRALIA: Perceval prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency.

TOP POTENTIAL SIDE EFFECTS: non-structural dysfunction, cardiac conduction disorders, structural valve deterioration, thromboembolism.

MRI conditiona

For professional use. Instructions for Use are available upon request through the manufacturer's website. Not approved in all geographies. Consult your labeling.



Manufactured by:

Corcym S.r.l.

Manufacturing site: Via Crescentino sn 13040 Saluggia (VC) Italy Tel: +39 0161 487800

Corcym Canada Corp.

Manufacturing site: 5005 North Fraser Way Burnaby, BC V5J 5M1 Canada Tel: +604 412-5650

Corcym Canada Corp. previously LivaNova Canada Corp.





© 2022 all rights reserved